Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 63Thoracic 16Gastrointestinal 12Breast 10CNS 9Sarcoma 8Head & Neck 8Gynecologic 8Genitourinary 7Other solid neoplasm 6Endocrine 6Lymphoid 4NET 2Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 382Leukemia, Myeloid, Acute 356Precursor Cell Lymphoblastic Leukemia-Lymphoma 184Leukemia 149Leukemia, Myelogenous, Chronic, BCR-ABL Positive 147Leukemia, Myelomonocytic, Chronic 128Myeloproliferative Disorders 114Leukemia, Lymphocytic, Chronic, B-Cell 100Primary Myelofibrosis 99Multiple Myeloma 89Lymphoma, Non-Hodgkin 89Hodgkin Disease 76Blast Crisis 68Lymphoma 62Leukemia, Myeloid, Chronic-Phase 58Lymphoma, Large B-Cell, Diffuse 53Lymphoma, Mantle-Cell 52Lymphoma, Follicular 52Burkitt Lymphoma 52Hematologic Neoplasms 51Leukemia, Myeloid, Accelerated Phase 50Congenital Abnormalities 47Polycythemia Vera 45Lymphoma, B-Cell, Marginal Zone 44Thrombocythemia, Essential 43Lymphoma, Large-Cell, Immunoblastic 43Anemia, Refractory, with Excess of Blasts 42Myelodysplastic-Myeloproliferative Diseases 41Neoplasms, Plasma Cell 40Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 40

Interventions

ruxolitinib 1avelumab 1Pemetrexed 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Uveal Melanoma × Myeloid × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡